Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 13Neoplasms 6Neoplasm Metastasis 4Thoracic Neoplasms 2Noonan Syndrome 2NSCLC 2Meningeal Carcinomatosis 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1T790M Positive NSCLC Patients 1Solid Tumor 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Renal Insufficiency 1Progression Free Survival 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer Metastatic 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Lung Diseases 1Locally Advanced or Metastatic EGFR T790M+ NSCLC 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1

Interventions

Temozolomide 203Radiotherapy 118Bevacizumab 93Radiation 40Magnetic Resonance Spectroscopy 28Irinotecan 27Carmustine 25Surgical Procedures, Operative 24Lomustine 21Erlotinib Hydrochloride 19Chemotherapy, Adjuvant 18Carboplatin 17temsirolimus 13Drug Therapy 13O(6)-benzylguanine 12Nivolumab 12sargramostim 11Sirolimus 11Radiotherapy, Intensity-Modulated 11Radiotherapy, Conformal 11Sorafenib 10Radiosurgery 10Imatinib Mesylate 10Everolimus 10pembrolizumab 9motexafin gadolinium 9Vorinostat 9Thalidomide 8IL13-PE38 8Gefitinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioblastoma × osimertinib × Clear all
NCT03732352 2024-11-12

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Jonsson Comprehensive Cancer Center

Phase 2 Completed
12 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡